Novaremed Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$50M
- Investors
-
3
Novaremed General Information
Description
Developer of pharmaceutical drugs using small bio-molecules designed for the treatment of neuropathic pain. The company develops an orally active non-opioid small molecule with a novel mechanism of action against podoplanin (PDPN), which is a tyrosine kinase modulator to be used for the treatment of neuropathic pain, enabling doctors and healthcare organizations to treat neuropathy-related diseases, especially diabetic neuropathic pain, effectively.
Contact Information
Website
www.novaremed.comCorporate Office
- Thiersteinerallee 17
- 4053 Basel
- Switzerland
Corporate Office
- Thiersteinerallee 17
- 4053 Basel
- Switzerland
Novaremed Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 28-Jan-2021 | $50M | Completed | Clinical Trials - Phase 2 | ||
| 7. Later Stage VC | 15-Sep-2020 | Completed | Clinical Trials - Phase 2 | |||
| 6. Later Stage VC | 02-Sep-2019 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC | 23-Aug-2018 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC | 17-Apr-2018 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC | Completed | Clinical Trials - General | ||||
| 2. Accelerator/Incubator | 23-Jan-2009 | $617K | $617K | Completed | Clinical Trials - General | |
| 1. Grant | 01-Nov-2008 | $1.14M | Completed | Clinical Trials - General |
Novaremed Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 606,452 | $0.109923 | $10.83 | $10.83 | 1x | $10.83 | 16.83% | |
| Ordinary | 453,179 | $0.109923 | $10.77 | $10.77 | 1x | $10.77 | 12.58% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Novaremed Patents
Novaremed Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026037478-A1 | (s,s)-(3-o-(propan-2-ol)-2-amino-prop-1-yl-4-hydroxybenzene and its analogues for the treatment of chronic pain | Pending | 11-Aug-2023 | ||
| EP-3939578-A1 | Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease | Inactive | 13-Jul-2020 | ||
| AU-2020210831-A1 | Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity | Active | 23-Jan-2019 | ||
| AU-2020210831-B2 | Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity | Active | 23-Jan-2019 | ||
| EP-3860582-A1 | Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity | Active | 23-Jan-2019 | C07C233/22 |
Novaremed Signals
Novaremed Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Global Emerging Markets | PE/Buyout | Minority | ||
| Gefen Biomed Investments | Venture Capital | Minority | ||
| Biomedix Incubator | Accelerator/Incubator | Minority |
Novaremed Acquisitions (1)
Novaremed’s most recent deal was a Merger/Acquisition with Metys Pharmaceuticals. The deal was made on 07-Sep-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Metys Pharmaceuticals | 07-Sep-2021 | Merger/Acquisition | Drug Discovery |
Novaremed FAQs
-
When was Novaremed founded?
Novaremed was founded in 2008.
-
Where is Novaremed headquartered?
Novaremed is headquartered in Basel, Switzerland.
-
What is the size of Novaremed?
Novaremed has 10 total employees.
-
What industry is Novaremed in?
Novaremed’s primary industry is Drug Discovery.
-
Is Novaremed a private or public company?
Novaremed is a Private company.
-
What is Novaremed’s current revenue?
The current revenue for Novaremed is .
-
How much funding has Novaremed raised over time?
Novaremed has raised $75.2M.
-
Who are Novaremed’s investors?
Global Emerging Markets, Gefen Biomed Investments, and Biomedix Incubator have invested in Novaremed.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process